Lixisenatide: First Global Approval
@article{Elkinson2013LixisenatideFG, title={Lixisenatide: First Global Approval}, author={Shelley Elkinson and Gillian M. Keating}, journal={Drugs}, year={2013}, volume={73}, pages={383-391} }
The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia®) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin secretion in a glucose-dependent manner, as well as suppressing glucagon production and slowing gastric emptying. A once-daily subcutaneous formulation of lixisenatide has been…
27 Citations
Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
- Medicine, BiologyClinical Diabetes
- 2016
This article provides a review of lixisenatide, a once-daily GLP-1 receptor agonist for the treatment of type 2 diabetes.
Lixisenatide: a guide to its use as add-on therapy in type 2 diabetes mellitus
- Medicine, Biology
- 2013
In clinical trials in this patient population, add-on therapy with once-daily subcutaneous lixisenatide improved glycaemic control, had beneficial effects on bodyweight and was generally well tolerated.
Lixisenatide as add-on therapy to basal insulin
- MedicineDrug design, development and therapy
- 2013
Lixisenatide exerts profound effects on postprandial glucose through established mechanisms of glucose-dependent insulin secretion and glucagon suppression in combination with delayed gastric emptying, making it a novel incretin agent for use in combinationWith optimally titrated basal insulin.
Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson's disease.
- Biology, Chemistry
- 2015
Both liraglutide and lixisenatide are superior to exendin-4, and both drugs show promise as a novel treatment of PD.
Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
- Biology, ChemistryNeuroscience
- 2015
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
- BiologyThe Journal of endocrinology
- 2014
GLP-1 mimetics show great promise as a novel treatment for neurodegenerative conditions because of the substantial body of evidence that these mimetics have neuroprotective and anti-inflammatory effects.
AUTHOR COPY ONLY Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
- Biology
- 2014
GLP-1 mimetics show great promise as a novel treatment for neurodegenerative conditions because of the substantial body of evidence that these mimetics have neuroprotective and anti-inflammatory effects.
Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease
- Biology, ChemistryNeuropharmacology
- 2014
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon.
- Biology, MedicineInternational review of cell and molecular biology
- 2016
The effect of liraglutide on endothelial function in patients with type 2 diabetes
- MedicineDiabetes & vascular disease research
- 2014
Liraglutide did not significantly impact endothelium-dependent vasodilation after 12 weeks; however, additional investigations looking at the effect of liragLutide on endothelial function in alternative vasculature and during the postprandial period are warranted.
References
SHOWING 1-10 OF 36 REFERENCES
The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist
- Medicine, Biology
- 2011
Clinical trials involving patients with T2DM have provided evidence for improved glucose tolerance, weight loss and lowered hemoglobin A1c (HbA1c) causing a significantly higher percentage of patients to achieve target HbA 1c compared with placebo.
Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
- Medicine, BiologyIDrugs : the investigational drugs journal
- 2009
The results of phase III trials are awaited for confirmation of the anticipated effects of lix Eisenatide on glycemic measures and weight; favorable results would place lixisenatide for consideration among other GLP-1R agonists in the treatment armamentarium for T2DM.
Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes
- MedicineAdvances in Therapy
- 2013
Lixisenatide improves glycemic control, by primarily affecting PPG, while preventing weight gain or reducing body weight with a low risk of hypoglycemia in T2DM.
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
- Biology, MedicineRegulatory Peptides
- 2010
Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus
- Medicine, BiologyDrugs
- 2012
A brief overview of the mechanism of action is given, the clinical data available on exenatide and liraglutide as established substances are summarized and the placement of GLP-1 receptor agonists in the treatment algorithm of type 2 diabetes is discussed.
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia
- MedicineRegulatory Peptides
- 2013
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
- MedicineDiabetes Care
- 2012
Once-daily lixisenatide monotherapy significantly improved glycemic control with a pronounced postprandial effect (75% reduction in glucose excursion) and was safe and well tolerated in type 2 diabetes.
Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression in db/db Mice
- Biology, MedicineJournal of Pharmacology and Experimental Therapeutics
- 2003
Long-term treatment of diabetic db/db mice with ZP10A resulted in a dose-dependent improvement of FBG, glucose tolerance, and blood glucose control, and the data suggest that ZP 10A preserves β-cell function.
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
- MedicineDiabetic medicine : a journal of the British Diabetic Association
- 2010
Diabet. Med. 27, 1024–1032 (2010)
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)*
- MedicineDiabetes, obesity & metabolism
- 2012
To assess the efficacy and safety of once‐daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal insulin ± sulfonylurea, a large number of patients will need to be referred to Europe for further studies.